Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience

• Published in: Clinics and practice 2023-08, Vol.13 (5), p.1015-1024
• Main Authors: Tabella, Erika, Correale, Michele, Alcidi, Gianmarco, Pugliese, Rosanna, Ioannoni, Sara, Romano, Matteo, Palmieri, Gianpaolo, Di Biase, Matteo, Brunetti, Natale Daniele, Iacoviello, Massimo
• Format: Article
• Language: English
• Subjects: angiotensin receptor neprylisin inhibitors; Beta blockers; Creatinine; Diabetes; Diuretics; Drug dosages; Ejection fraction; Heart failure; Hypertension; Hypotension; Ischemia; Reimbursement; therapy; type-2 sodium–glucose cotransporters inhibitors
• ISSN: 2039-7283; 2039-7275; 2039-7283
• DOI: 10.3390/clinpract13050090

Background: The sodium–glucose cotransporter-2 inhibitors (SGLT2i) have emerged as a crucial therapeutic option for patients with chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate, in a real-world population from a single centre, the feasibility of introducing SGLT2i and their interaction with other recommended drug classes. Methods: Consecutive patients affected by chronic heart failure (CHF) were evaluated beginning in January 2022. At the baseline clinical visit, both the patient’s current medication and the prescribed treatments were recorded. Over a 6- to 12-month follow-up, changes in concomitant therapy were analysed. Results: At baseline, among 350 patients evaluated, only 17 (5%) were already taking SGLT2i: 13 with HFrEF, five with mildly reduced (HFmrEF), preserved (HFpEF) or improved (HFimpEF) ejection fraction. After the baseline assessment, SGLT2i were prescribed to 224 (64%) of the patients, including 179 (84%) with HFrEF, 27 (42%) with HFmrEF/HFimpEF, and 18 (22%) with HFpEF/HFimpEF. After follow-up, SGLT2i therapy was well tolerated and was associated with a significant increase in sacubitril/valsartan prescriptions and a decrease in diuretic use. Finally, a significant improvement in functional status and left ventricular systolic function after SGLT2i therapy was observed. Conclusions: In this single-centre, real-world study, SGLT2i were primarily prescribed to HFrEF patients who were already on other recommended drug classes for their treatment. Additionally, there was a noticeable enhancement in the prescribed therapy during a short-term follow-up. These findings further bolster the inclusion of this therapeutic approach in regular clinical practice.